Latest Us Regulatory News

Page 3 of 9
Venari Minerals says it knows of no undisclosed information behind a sharp rise in its share price and trading volume. The company points instead to ongoing Red Mountain drilling and a proposed exploration program still awaiting US regulatory approval.
Maxwell Dee
Maxwell Dee
10 Sept 2026
Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.
Victor Sage
Victor Sage
10 Sept 2026
Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.
Ada Torres
Ada Torres
10 Sept 2026
Elixinol Wellness has finalized the divestment of its US operations to Ananda Health, securing upfront and deferred payments totaling approximately A$465,000. This move refocuses the company on its Australian health and wellness portfolio while reducing exposure to US regulatory risks.
Victor Sage
Victor Sage
7 Sept 2026
Optiscan Imaging has launched a 35-patient clinical trial in the US to test its InVue™ and InForm™ platforms in head and neck cancer surgery, aiming to bolster its FDA submissions later this year.
Ada Torres
Ada Torres
1 Sept 2026
Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.
Ada Torres
Ada Torres
31 Aug 2026
AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.
Ada Torres
Ada Torres
21 Aug 2026
SQX Resources launches a fully underwritten $2.47 million rights issue at a 31% discount to fund accelerated exploration across key US and Australian projects.
Maxwell Dee
Maxwell Dee
21 Aug 2026
Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.
Ada Torres
Ada Torres
17 Aug 2026
Dateline Resources faces a US court injunction halting operations at its Colosseum Project, while ASX suspends and then reinstates trading over disclosure timing concerns.
Maxwell Dee
Maxwell Dee
12 Aug 2026
AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.
Ada Torres
Ada Torres
10 Aug 2026
OD6 Metals has completed its acquisition of the Quinn Fluorspar Project, consolidating 100% ownership of 226 mining claims in Nevada and positioning itself as a potential key domestic fluorspar supplier for the US.
Maxwell Dee
Maxwell Dee
4 Aug 2026

Browse the archive

Full archive